The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.
The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.
[DE] SUBSTITUIERTE CHROMANOL-DERIVATE UND IHRE VERWENDUNG<br/>[EN] SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE<br/>[FR] DERIVE DE CHROMANOL SUBSTITUE ET SON UTILISATION
申请人:BAYER HEALTHCARE AG
公开号:WO2007107243A1
公开(公告)日:2007-09-27
[EN] The present application relates to substituted chromanol derivatives, to processes for their preparation, to their use alone or in combinations for treatment and/or prevention of diseases and to their use for producing medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular disorders. [FR] La présente invention concerne un dérivé de chromanol substitué, son procédé de fabrication, son utilisation seul ou en combinaison pour le traitement et/ou la prévention de maladies, ainsi que son utilisation pour la fabrication de médicaments pour le traitement et/ou la prévention de maladies, notamment pour le traitement et/ou la prévention de maladies cardiovasculaires. [DE] Die vorliegende Anmeldung betrifft substituierte Chromanol-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von kardiovaskulären Erkrankungen.
Chromanol derivatives—A novel class of CETP inhibitors
作者:Alexandros Vakalopoulos、Carsten Schmeck、Michael Thutewohl、Volkhart Li、Hilmar Bischoff、Klemens Lustig、Olaf Weber、Holger Paulsen、Harry Elias
DOI:10.1016/j.bmcl.2010.10.110
日期:2011.1
Based on our former development candidate BAY 38-1315, optimization efforts led to the discovery of a novel chemical class of orally active cholesteryl ester transfer protein (CETP) inhibitors. The chromanol derivative 19b is a highly potent CETP inhibitor with favorable pharmacokinetic properties suitable for clinical studies. Chemical process optimization furnished a robust synthesis for a kilogram-scale process. (C) 2010 Elsevier Ltd. All rights reserved.